Intero Biosystems Wins Disrupt 2026 With Lab-Grown Guts

A Denver biotech startup that grows miniature human intestines in a laboratory has just beaten the rest of the field to the biggest trophy in startup competitions. Intero Biosystems took the Startup Battlefield crown at TechCrunch Disrupt 2026 this week, winning the Disrupt Cup and a cash prize for GastroScreen, a testing platform built on lab-grown gut tissue that lets drugmakers see how new medicines behave before anything ever reaches a human trial.

The win caps three days of live pitching in San Francisco, where the competing startups were drawn from a broader two-hundred-company shortlist. According to TechCrunch, the final round came down to five companies: scam-fighting bot maker Apate, wildlife-detection outfit Flox Intelligence, factory-robotics firm Industrial Next, orbital-computing startup Satlyt, and the eventual winner. The judging panel was stacked with venture capital names including Alexa von Tobel, Chi-Hua Chien, Dayna Grayson, Karl Alomar and Stacy Brown-Philpot.

What the company actually sells

Intero Biosystems was founded by Charlie Childs and Madeline Eiken as a spinout of the University of Michigan. Its core technology is a one-millimeter intestinal organoid: a tiny piece of lab-grown tissue that mimics the structure and function of the human gut, containing multiple cell and tissue types rather than a simplified model of just one part of the organ.

The company sells that technology as GastroScreen to pharmaceutical, biotech, food and chemical companies, which use the organoids to test drugs and other compounds for safety and effect before committing to expensive and risky human trials. The idea is to catch doomed compounds earlier, when failure is cheap, and to do it with a model closer to human biology than a dish of single cells.

Reported by Startup Researcher, the winnings — one hundred thousand dollars in equity-free funding — are earmarked to help the young company validate its results against existing animal and clinical data and scale up manufacturing. That validation step is the entire business: GastroScreen is only worth buying if its predictions reliably line up with what happens in real bodies, and the prize money buys the head-to-head studies that prove it.

How the contest played out

The competition ran over three days, with each startup delivering a live demo in front of venture capitalists and technology leaders serving as judges. TechCrunch editors then reviewed the judges' notes and cut the field to five finalists, who returned for a final pitch round in front of the senior judging panel before the winner was announced on the closing day.

The rest of the finalist lineup shows where investor attention is pooling right now. Apate sends AI agents undercover to waste scammers' time and expose their bank accounts. Satlyt runs AI workloads on computers already in orbit. Industrial Next teaches factory robots new jobs in minutes rather than weeks, and Flox Intelligence uses AI to keep wild animals safely away from runways, railways and roads. Against that roster, a gut in a dish might sound old-fashioned — but the judges went with biology, a reminder that ambitious software is only part of the story told by stories like ZYMIX Superapp Unites Chat, Payments and AI in One App.

Why a gut in a dish matters for everyone else

Drug development is famous for burning cash: most compounds that enter testing never become medicines, and failures discovered late cost fortunes. A more human-relevant preclinical model could flag toxicity and bad absorption before a company spends millions on trials — and over time reduce the industry's reliance on animal testing. That is the bet Intero Biosystems is making: that a millimeter of gut can tell you more than a cage of mice.

Regulators are starting to clear a path for exactly this kind of technology. As reported by Runtime Wire, federal drug regulators have been issuing guidance that gives developers a framework for evaluating non-animal testing alternatives. That matters because even the best organoid is only as useful as the system willing to accept its results, and official guidance is what turns a clever lab trick into an industry standard.

For readers, the payoff is indirect but real. Better preclinical screening means fewer doomed drugs reaching human trials, which means development money stretches further and experimental medicines fail faster and cheaper instead of dragging through years of testing. It could even reach your kitchen shelf: food additives and supplements may one day be screened on tissue that behaves like your own gut rather than on a proxy that does not. AI is already reshaping how medicine gets researched and judged, as AI Just Mapped the DNA of the Dodo Comeback shows from the research side.

A contest with a serious pedigree

The Battlefield has launched names that went on to matter far beyond startup land. TechCrunch's own retrospective notes that Cloudflare launched at Disrupt back in 2010, and the competition's alumni have become a fixture of how Silicon Valley scouts new companies. If the winner follows even a fraction of that trajectory, this week's trophy will look like a bargain by the standards of biotech.

What comes next is the unglamorous part: proving the science with data. The company must now show that GastroScreen's results reproduce reliably and line up with animal and human outcomes — the validation work that turns a clever demo into a product pharma actually trusts. The Disrupt Cup gets the headline; the spreadsheets get the customers. Even the hardware world is getting the same rigorous teardown treatment, as Your Next Phone Ships With a Repair Grade Most Brands Flunk demonstrates.